

1 **Supplementary Table 1.** Clinical and demographic data of patients with chronic hypertrophic
 2 tonsillar diseases with HBoV1 detected in adenoid plus co-detection of other respiratory viruses.
 3

Features	HBoV1 alone N (%)	HBoV1 + 1 virus N (%)	HBoV + 2 viruses N (%)	HBoV + 3 viruses N (%)	HBoV + 4 viruses N (%)
Patients	6 (13.6%)	15 (34.0%)	18 (40.9)	4 (9.1%)	1 (2.2%)
Masculine gender	5 (83.3%)	8 (53.3%)	12 (66.6%)	3 (75%)	1 (100%)
Age (median of years)	5.0	4.0	4.0	4.0	5.0
0-50% airway obstruction	0 (0.0%)	1 (6.6%)	1 (5.5%)	1 (25%)	0 (0.0%)
50-75% airway obstruction	3 (50.0%)	4 (26.6%)	7 (38.8%)	3 (75%)	0 (0.0%)
75-100% airway obstruction	3 (50.0%)	10 (66.6%)	10 (55.5%)	0 (0.0%)	1 (100%)
Sleep apnea	5 (83.3%)	10 (66.6%)	11 (61.1%)	2 (50.0%)	1 (100%)
Secretory otitis media	3 (50.0%)	2 (13.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Allergies	2 (33.3%)	3 (20.0%)	6 (33.3%)	0 (0.0%)	1 (100%)

4
 5
 6 **Supplementary Table 2.** Clinical and demographic data of patients with chronic hypertrophic tonsillar
 7 diseases with HBoV1 detected in palatine tonsils plus co-detection of other respiratory viruses.
 8

Features	HBoV1 alone N (%)	HBoV1 + 1 virus N (%)	HBoV + 2 viruses N (%)	HBoV + 3 viruses N (%)
Patients	3 (23.1%)	5 (38.4%)	3 (23.1%)	2 (15.4%)
Masculine gender	1 (33.3%)	1 (20.0%)	2 (66.6%)	2 (100%)
Age (median of years)	6.0	4.0	4.0	4.5
Recurrent tonsillitis	2 (66.6%)	2 (40.0%)	0 (0.0%)	2 (100%)
Tonsillar hypertrophy	2 (66.6%)	4 (80.0%)	3 (100%)	2 (100%)
Sleep apnea	2 (66.6%)	5 (100%)	3 (100%)	1 (50.0%)
Secretory otitis media	0 (0.0%)	0 (0.0%)	1 (33.3%)	0
Allergies	1 (33.3%)	0 (0.0%)	0 (0.0%)	1 (50.0%)

9
 10
 11 **Supplementary Table 3.** Clinical and demographic data of patients with detectable HBoV1 VP1 or
 12 NP1 mRNAs in adenoids.
 13
 14

	Hypertrophic Patients		Control Patients	
	mRNA +	mRNA -	mRNA +	mRNA -
Patients	12	32	0	4
Masculine gender	9 (75.0%)	20 (62.5%)	-	3 (75.0%)
Age (median of years)	4.0	4.0	-	2.0
Viral co-infection	38 (86.4%)	69 (53.1%)	-	2 (50.0%)
Viral load (median copies/g)*	2.3x10 ⁷	6.6x10 ⁵	-	4.1x10 ⁴
High viral load (>10 ⁶)*	10 (83.3%)	13 (40.6%)	-	0 (0.0%)
Detection in several sites*	8 (66.6%)	7 (21.8%)	-	1 (25%)
HBoV1 shedding in NPS*	6 (50.0%)	6 (18.7%)	-	1 (25%)
0-50% airway obstruction	1 (8.3%)	2 (6.2%)	-	-
50-75% airway obstruction	5 (41.6%)	12 (37.5%)	-	-
75-100% airway obstruction	6 (50.0%)	18 (56.2%)	-	-
Sleep apnea	7 (58.3.9%)	22 (68.7%)	-	-
Secretory otitis media	0 (0.0%)	5 (15.6%)	-	-
Allergies	4 (33.3%)	8 (25.0%)	-	-

15
 16 * p<0.05.
 17
 18
 19
 20

21 **Supplementary Table 4.** Clinical and demographic data of patients with detectable HBoV1 VP1 or
 22 NP1 mRNAs in palatine tonsils.
 23
 24

	Hypertrophic Patients		Control Patients	
	mRNA +	mRNA -	mRNA +	mRNA -
Patients	1	12	-	-
Masculine gender	1 (100%)	5 (41.6%)	-	-
Age (median of years)	5.0	4.0	-	-
Viral co-infection	1 (100%)	9 (75.0%)	-	-
Viral load (median copies/g)	2.2x10 ⁹	8.4x10 ⁴	-	-
High viral load (>10 ⁶)	1 (100%)	2 (16.6%)	-	-
Detection in several sites	1 (100%)	6 (50.0%)	-	-
HBoV1 shedding in NPS	0 (0.0%)	1 (8.3%)	-	-
Recurrent tonsillitis	1 (100%)	5 (41.6%)	-	-
Tonsillar hypertrophy	1 (100%)	10 (83.3%)	-	-
Sleep apnea	1 (100%)	10 (83.3%)	-	-
Secretory otitis media	0 (0.0%)	1 (8.3%)	-	-
Allergies	1 (100%)	1 (8.3%)	-	-

25
 26
 27 **Supplementary Table 5.** Frequency of mRNA detection in adenoids (AD), palatine tonsils (PT) and
 28 nasopharyngeal secretions (NPS) from patients with single HBoV1 infection and in those co-infected
 29 by one to four additional respiratory viruses.
 30

Viruses Detected	AD		PT		NPS	
	mRNA + N (%)	mRNA - N (%)	mRNA + N (%)	mRNA - N (%)	mRNA + N (%)	mRNA - N (%)
Only HBoV	1 (8.3)	5 (15.6)	0 (0.0)	3 (25.0)	0 (0.0)	3 (20.0)
HBoV + HAdV	2 (16.7)	6 (18.8)	0 (0.0)	3 (25.0)	0 (0.0)	3 (20.0)
HBoV + HRV	0 (0.0)	1 (3.1)	0 (0.0)	1 (8.3)	0 (0.0)	1 (6.7)
HBoV + HEV	0 (0.0)	4 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)	2 (13.3)
HBoV + HRSV	0 (0.0)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
HBoV + HMPV	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)
HBoV + FLU	0 (0.0)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
HBoV + HAdV + HRV	2 (16.7)	3 (9.4)	0 (0.0)	0 (0.0)	1 (25.0)	2 (13.3)
HBoV + HAdV + HEV	2 (16.7)	3 (9.4)	0 (0.0)	3 (25.0)	0 (0.0)	2 (13.3)
HBoV + HAdV + HRSV	0 (0.0)	1 (3.1)	0 (0.0)	0 (0.0)	1 (25.0)	0 (0.0)
HBoV + HAdV + HMPV	0 (0.0)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
HBoV + HRV + HEV	0 (0.0)	1 (3.1)	0 (0.0)	0 (0.0)	1 (25.0)	1 (6.7)
HBoV + HRV + HRSV	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (6.7)
HBoV + HRV + HCoV	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	0 (0.0)
HBoV + HEV + HMPV	0 (0.0)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
HBoV + HEV + HPIV	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
HBoV + HMPV + HPIV	0 (0.0)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
HBoV + FLU + HPIV	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
HBoV + HAdV + HRV + HRSV	0 (0.0)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
HBoV + HAdV + HEV + HRSV	0 (0.0)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
HBoV + HAdV + HEV + HMPV	0 (0.0)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
HBoV + HAdV + HEV + HCoV	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
HBoV + HAdV + HEV + HPIV	0 (0.0)	0 (0.0)	1 (100)	0 (0.0)	0 (0.0)	0 (0.0)
HBoV + HEV + FLU + HPIV	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)
HBoV + HAdV + HEV + HRSV + HPIV	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
TOTAL	12 (27.3)	32 (72.7)	1 (7.7%)	12 (92.3)	4 (21.0)	15 (79.0)

31
 32
 33